Payment overview · 2025
General Payments
$480.12
21 reported records · 9 companies
Healthcare provider profile · identity verified
John C Peters, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · NEW HYDE PARK, NY · NPI 1073628889
Verified facts
What the public records show
CMS Open Payments records show John C Peters, MD received $480.12 in general payments during 2025 across 21 reported records.
Amgen Inc. accounted for 39.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Synthroid by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $189.79 | 39.5% | 6 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $72.81 | 15.2% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $50.73 | 10.6% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $36.68 | 7.6% | 2 | 2025 |
| OPKO Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $32.23 | 6.7% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $29.64 | 6.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.44 | 5.1% | 1 | 2025 |
| BridgeBio Pharma, Inc. | Unresolved — no canonical attribution shown | $23.86 | 5.0% | 1 | 2025 |
| Rhythm Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.94 | 4.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $480.12 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $189.79 | 6 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $72.81 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $50.73 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $50.73 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $36.68 | 2 | 2025 |
Source payment records
|
|||||
| RAYALDEE Normalized: rayaldee |
Drug | OPKO Pharmaceuticals, LLC | $32.23 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $29.64 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $29.64 | 1 | 2025 |
Source payment records
|
|||||
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $24.44 | 1 | 2025 |
Source payment records
|
|||||
| Attruby Normalized: attruby |
Drug | BridgeBio Pharma, Inc. | $23.86 | 1 | 2025 |
Source payment records
|
|||||
| IMCIVREE Normalized: imcivree |
Drug | Rhythm Pharmaceuticals, Inc. | $19.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 510 | 148 |
| Atorvastatin Calcium | Atorvastatin Calcium | 398 | 120 |
| Losartan Potassium | Losartan Potassium | 383 | 119 |
| Amlodipine Besylate | Amlodipine Besylate | 335 | 104 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 328 | 112 |
| Alprazolam | Alprazolam | 279 | 63 |
| Simvastatin | Simvastatin | 243 | 67 |
| Eliquis | Apixaban | 226 | 60 |
| Nebivolol Hcl | Nebivolol Hcl | 179 | 54 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 174 | 55 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 174 | 59 |
| Levothyroxine Sodium | Levothyroxine Sodium | 162 | 39 |
| Atenolol | Atenolol | 139 | 41 |
| Xarelto | Rivaroxaban | 130 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 128 | 47 |
| Metoprolol Tartrate | Metoprolol Tartrate | 124 | 40 |
| Furosemide | Furosemide | 113 | 36 |
| Eszopiclone | Eszopiclone | 104 | 20 |
| Allopurinol | Allopurinol | 100 | 31 |
| Meloxicam | Meloxicam | 96 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 94 | 19 |
| Omeprazole | Omeprazole | 92 | 29 |
| Ezetimibe | Ezetimibe | 90 | 30 |
| Carvedilol | Carvedilol | 86 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 85 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 85 | 32 |
| Lisinopril | Lisinopril | 84 | 23 |
| Potassium Chloride | Potassium Chloride | 84 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 80 | 23 |
| Enalapril Maleate | Enalapril Maleate | 77 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 74 | 26 |
| Clonazepam | Clonazepam | 70 | 15 |
| Azithromycin | Azithromycin | 66 | 52 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 63 | 17 |
| Montelukast Sodium | Montelukast Sodium | 63 | 18 |
| Levofloxacin | Levofloxacin | 62 | 43 |
| Prasugrel Hcl | Prasugrel Hcl | 55 | 18 |
| Spironolactone | Spironolactone | 55 | 15 |
| Methylprednisolone | Methylprednisolone | 54 | 40 |
| Sertraline Hcl | Sertraline Hcl | 53 | 15 |
| Propranolol Hcl | Propranolol Hcl | 51 | 20 |
| Labetalol Hcl | Labetalol Hcl | 50 | 16 |
| Gabapentin | Gabapentin | 47 | 18 |
| Nadolol | Nadolol | 45 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 40 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 39 | 13 |
| Lorazepam | Lorazepam | 37 | suppressed |
| Febuxostat | Febuxostat | 34 | 14 |
| Klor-Con M20 | Potassium Chloride | 34 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 33 | 12 |
| Synthroid | Levothyroxine Sodium | 32 | suppressed |
| Valsartan | Valsartan | 32 | suppressed |
| Edarbi | Azilsartan Medoxomil | 31 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 31 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 30 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | 13 |
| Pitavastatin Calcium | Pitavastatin Calcium | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Entresto | Sacubitril/Valsartan | 28 | suppressed |
| Metformin Hcl | Metformin Hcl | 28 | 11 |
| Mometasone Furoate | Mometasone Furoate | 28 | suppressed |
| Diazepam | Diazepam | 27 | suppressed |
| Sotalol | Sotalol Hcl | 26 | suppressed |
| Telmisartan | Telmisartan | 26 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Famotidine | Famotidine | 23 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 23 | suppressed |
| Prednisone | Prednisone | 23 | 16 |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 22 | suppressed |
| Digoxin | Digoxin | 21 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 20 | suppressed |
| Multaq | Dronedarone Hcl | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 16 |
| Colchicine | Colchicine | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Pindolol | Pindolol | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 16 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Livalo | Pitavastatin Calcium | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $480.12 · 21 records | Amgen Inc. | AREXVY, AVEIR, Attruby, IMCIVREE, LEQVIO, QULIPTA, RAYALDEE, REPATHA, SHINGRIX, UBRELVY, Wegovy | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error